Insmed Q4 2023 Adj EPS $(1.28) Misses $(1.15) Estimate, Sales $83.70M Beat $82.76M Estimate
Portfolio Pulse from Benzinga Newsdesk
Insmed (NASDAQ:INSM) reported Q4 2023 adjusted EPS of $(1.28), missing the $(1.15) estimate, but sales of $83.70M exceeded the $82.76M estimate, marking a 41.15% increase from the same period last year.
February 22, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Insmed reported a Q4 2023 adjusted EPS of $(1.28), missing estimates, but sales of $83.70M exceeded expectations, showing significant growth.
The missed EPS estimate may negatively impact investor sentiment in the short term, but the sales beat and significant year-over-year growth could offset this, leading to a neutral short-term price direction.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100